Future Oncology

Article	Citations
Spectrum of Lymphoma Subtypes Based on the Latest World Health Organization Classification in Southern Iran from 2000 to 2011	101
Bidirectional Deep Neural Networks to Integrate RNA and DNA Data for Predicting Outcome for Patients with Hepatocellular Carcinoma	78
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma	72
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary	65
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer	58
Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case–control study	57
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	52
Association of Facility Type With Overall Survival in Patients with Nonsurgically Managed Pancreatic Cancer	47
A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer	43
Nomogram Predicting Prostate Cancer in Patients with Negative Prebiopsy Multiparametric Magnetic Resonance	41
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TAL	39
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study	39
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma	38
Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects	37
Cutaneous Adverse Events Associated with PD-1 Inhibitor-based Therapy in Patients with Non-Small-Cell Lung Cancer	36
An observational study of hospitalized COVID-19 patients with cancer in San Diego county	36
Decoding clinical trial jargon: helping people understand theefficacy end points used in cancer trials	36
6 th Symposium on Primary Breast Cancer in Older Women	35
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	35
Prognostic Factors Affecting Infantile Medulloblastoma Outcomes in the Molecular Era: A 12-year Single-Center Experience from Egypt	34
Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma	32
Resveratrol and miR-200c: insights into the prevention of oral squamous cell carcinoma	31
Capecitabine Maintenance Therapy in Metastatic Colorectal Cancer Patients with no Evidence of Disease: CAMCO Trial	30
miRNA-767 and its binding site polymorphism in the mTOR gene act as potential biomarkers for female reproductive cancers	30
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	29

The Power of Hope: Views of Ovarian Cancer Patients on How Maintenance Therapy Affects Their Lives (VOCAL)	28
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	28
Sex bias phenomenon in oral cancer: an insight	28
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	28
Prognostication for Surgically Treated Papillary Renal Cell Carcinoma: Which Model is the Optimal Choice?	28
Prediction model based on radiomics and clinical features for preoperative lymphovascular invasion in gastric cancer patients	28
Daratumumab in Indian Patients with Relapsed and Refractory Multiple Myeloma: A Prospective, Multicenter, Phase IV Study	27
Corrigendum	26
Plain Language Summary of the Final Results from the GioTag Study	26
First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population	25
First Advanced Course on Biomarkers in Molecular and Immuno-Oncology in the Middle East	25
Predicting Amplification of MYCN using CpG Methylation Biomarkers in Neuroblastoma	25
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial)	25
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary	25
The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer	24
Corrigendum	24
Cabozantinib Plus Immunotherapy Combinations in Metastatic Renal Cell and Urothelial Carcinoma	24
Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer: A Plain Language Summary of the DESTINY-Breast03 Study	23
Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?	23
Actual situation of decision-making support from medical staff when cancer patients make treatment choices	23
Welcoming the 20th Volume of Future Oncology	23
Polymorphism in miRNA Target Sites of CEP-63 and CEP-152 Ring Complex Influences Expression of CEP Genes and Favors Tumorigenesis in Gliom	22
Plain Language Summary of the CROWN Study Comparing Lorlatinib with Crizotinib for People with Untreated Non-Small Cell Lung Cancer	22
Acalabrutinib and its use in the Treatment of Chronic Lymphocytic Leukemia	22
Thoughts and Suggestions on the Fact That Dacomitinib Reduction did not Affect its Efficacy in the Archer 1050 Study	22
Cost–effectiveness of Immune Checkpoint Inhibitors in the Treatment of Non-Small-Cell Lung Cancer as a Second Line in Taiwan	21
Sorafenib and Hepatocellular Carcinoma: is Alpha-Fetoprotein a Biomarker Predictive of Tumor Biology and Primary Resistance?	21
Real-world Outcomes with Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma using SEER-Medicare Data	21
Can Pretreatment Blood Biomarkers Predict Pathological Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer?	21
Genetic Interactions of Mitochondrial Sirtuins in Brain Tumorigenesis	21
Highlights of the San Antonio Breast Cancer Symposium 2020: Part 1	20
New Landscapes in the Management of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Oral Decitabine	20
Developing an Immune Signature for Triple-Negative Breast Cancer to Predict Prognosis and Immune Checkpoint Inhibitor Response	20
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	20
Genetic Markers of Chronic Lymphocytic Leukemia: A Retrospective Study of 312 Patients from a Reference Center in Lebanon	19
Real-World Efficacy of Docetaxel Plus Nintedanib After Chemo-Immunotherapy Failure in Advanced Pulmonary Adenocarcinoma	19
The 7 th Symposium on Primary Breast Cancer in Older Women	19
Oral Submucous Fibrosis and Heterogeneity in Outcome Measures: A Critical Viewpoint	19
Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer	19
Dedifferentiated Chondrosarcoma: Current Standards of Care	19
Clinical and Laboratory Outcomes of the Solid Cancer Patients Reinfected with SARS-CoV-2	18
Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy	18
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	18
Large-scale Omics Data Reveal the Cooperation of Mutation-circRNA-miRNA-Target Gene Network in Liver Cancer Oncogenesis	18
Novel Imaging Strategies for Prostate Cancer	18
Patterns of Colorectal Cancer Diagnosis Among Younger Adults in a Real-World, Population-Based Cohort	18
Niraparib treatment for patients with BRCA -mutated ovarian cancer: review of clinical data and therapeutic context	18
Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study	18
High PD-L1 Expression on Immune Cells, But not on Tumor Cells, is a Favorable Prognostic Factor in Urothelial Carcinoma	18
Pembrolizumab for the treatment of advanced esophageal cancer	17

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)	17
Is Obesity a Risk Factor in Cancer Patients with COVID-19?	17
Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges	17
Cancer cytogenetics in the era of artificial intelligence: shaping the future of chromosome analysis	17
Achieving White Blood Cell Equity: Are the Safety Profiles of Biosimilar and Reference Pegfilgrastims Comparable?	17
30 years of PI3K: an interview with Bart Vanhaesebroeck	17
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	17
Olaparib for the Treatment of Metastatic Prostate Cancer	16
Effects of Genetic Polymorphisms of LINC-PINT Gene on Liver Cancer Susceptibility in the Chinese Han Population	16
State of Cancer Care in India and Opportunities for Innovation	16
Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R in liver cancer	16
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT	16
Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC	16
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice	16
Natural Orifice Specimen Extraction Surgery Versus Small-Incision Assisted Laparoscopic Radical Right Hemicolectomy	15
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	15
Clinical Activity and Safety of the Anti-PD-1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced dMMR Endometrial Cancer	15
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis	15
Real-world treatment patterns and overall survival in BRAF -mutant melanoma patients treated with immunotherapy or targeted therapy	15
Patient Preferences for Advanced Hepatocellular Carcinoma Treatment: A Multicountry Stated Preference Study	15
A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas	15
Application of Cherenkov Radiation in Tumor Imaging and Treatment	15
KEYSTEP-008: Phase II Trial of Pembrolizumab-Based Combination in MSI-H/dMMR Metastatic Colorectal Cancer	15
Age-Dependent Prognostic Value of KRAS Mutation in Metastatic Colorectal Cancer	15
ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue	15
Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice	15
Development and Validation of An Immune Gene Set-Based Prognostic Signature in Cutaneous Melanoma	15
Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA	15
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer	15
Venetoclax-Based Combinations for the Treatment of Newly Diagnosed Acute Myeloid Leukemia	14
The role of miRNAin prostate cancer diagnosis, prognosisand treatment response: a narrative review	14
Financial Toxicity and its Impact on Health Outcomes and Caregiver Burden Among Adult Cancer Survivors in the USA	14
CDK4/6 Inhibitors: Mechanisms of Resistance and Potential Biomarkers of Responsiveness in Breast Cancer	14
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Limited-Stage Small-Cell Lung Cancer: A Meta-Analysis	14
Oncoplastic Breast-Conservative Surgery for Breast Cancers: A Uni-Institutional Case–Control Study	14
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study	14
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies	13
Factors for Incidence Risk and Prognosis in Non-Small-Cell Lung Cancer Patients with Synchronous Brain Metastasis: A Population-Based Study	13
Single-Dose Netupitant/Palonosetron Versus 3-day Aprepitant for Preventing Chemotherapy-Induced Nausea and Vomiting: A Pooled Analysis	13
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients	13
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	13
Pragmatic Patient Engagement in Designing Pragmatic Oncology Clinical Trials	13
KRAS mutational analysis: a new supplementary diagnostic tool for extrahepatic biliary stenosis	13
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer	13
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	13
Clinical-Pathological Shrinkage Modes Could Help to Guide Breast-Conserving Surgery After Neoadjuvant Therapy	13
HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC	13
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma	13
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer	13
DUART: Durvalumab After Radiotherapy in Patients with Unresectable, Stage III NSCLC who are Ineligible for Chemotherapy	13
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer	13
Adjuvant EGFR Tyrosine Kinase Inhibitors for Patients with Resected EGFR -Mutated Non-Small-Cell Lung Cancer: A Network Meta-Analysis	12
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatment	12
A Concise Prognostic Score System for Diffuse Large B-Cell Lymphoma: A Retrospective Study with Long-Term Follow-Up	12
Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus	12
Stratification of Axillary Lymph Node Metastasis Risk with Breast MRI in Breast Cancer	12
Systemic Therapy, Survival and End-Of-Life Costs for Metastatic Triple-Negative Breast Cancer: Retrospective SEER-Medicare Study of Women Age ≥65 Years	12
Exploring Exosome Data to Identify Prognostic Gene Signatures for Lung Adenocarcinoma	12
Development and validation of prognostic nomograms in patients with hepatocellular carcinoma: a population-based study	12
Direct Costs of Antineoplastic and Supportive Treatment for Progressive Multiple Myeloma in a Tax-Based Health System	12
GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers	12
Withdrawal of Dacomitinib Treatment due to Absence of Toxicities is not Justified	12
Nivolumab in Gastric/Gastroesophageal Junction Cancer: Real-World Data from UK Early Access to Medicines Scheme	12
Real-World Outcomes for First Line Next-Generation Hormonal Agents in Metastatic Prostate Cancer: A Systematic Review	12
Patients’ and oncologists’ preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer	12
Pregnancy and Perinatal Outcomes Following Exposure to Antineoplastic Agents Around Pregnancy within the US FDA Adverse Event Reporting System	11
Frontline anti-PD-1/PD-L1 Versus Bevacizumab in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis	11
Real-World Homologous Recombination Repair Mutation Testing in Metastatic Castration-Resistant Prostate Cancer in the USA, Europe and Japan	11
Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer	11
A Phase III Trial of Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastasis	11
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	11
Indications for and Contraindications of Immune Checkpoint Inhibitors in Cancer Patients with COVID-19 Vaccination	11
Expression Profiles and Prognostic Roles of m6A Writers, Erasers and Readers in Gastric Cancer	11
Preferences of Adults with Cancer for Systemic Cancer Treatment: Do Preferences Differ Based on Age?	11
A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax Plus Docetaxel in Patients with Advanced Solid Tumors	11
Diagnosis, treatment and burden in advanced ovarian cancer: a UK real-world survey of healthcare professionals and patients	10
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	10
Effect of Lateral Lymph Nodes Without Malignant Characteristics on the Prognosis of Patients with Rectal Cancer	10
CaboPoint: A Phase II Study of Cabozantinib as Second-Line Treatment in Patients with Metastatic Renal Cell Carcinoma	10
The Implications from the Interplay of Neoadjuvant Chemoradiotherapy and the Immune Microenvironment in Rectal Cancer	10

From part to whole, operative link on to endoscopic grading of gastric intestinal metaplasia, pathology to endoscopy: gastric intestinal metaplasia graded by endoscopy	10
Protocol of the Integrated Boost to the Dominant Intraprostatic Nodule in Stereotactic Body Radiation Therapy for Localized Prostate Cancer	10
Efficacy and Safety of Dilpacimab (ABT-165) versus Bevacizumab Plus Folfiri in Metastatic Colorectal Cancer: A Phase II Study	10
Current Treatment Landscape of Pancreatic Cancer Patients in a Network of Office-based Oncologists in Germany	10
Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study	10
TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer	10
Evidence from a meta-analysis for the prognostic and clinicopathological importance of DKC1 in malignancies	9
Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals	9
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes	9
Physician Reported Treatment Patterns and Outcomes in Metastatic Bladder Cancer in the USA: The CancerMPact ® Survey 2020	9
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary	9
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	9
Outcomes of postoperative adjuvant transarterial chemoembolization for hepatocellular carcinoma according to the Ki67 index	9
siRNA-Based Approaches for Castration-Resistant Prostate Cancer Therapy Targeting the Androgen Receptor Signaling Pathway	9
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design	9
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors	9
Efficacy and Safety of Darolutamide in Black/African–American Patients from the Phase III ARAMIS Study	9
Margetuximab in HER2-positive metastatic breast cancer	9
Psychometric Properties of the 37-Item Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale	9
The BEETS (JACCRO CC-18) Trial: An Observational and Translational Study of BRAF -Mutated Metastatic Colorectal Cancer	9
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma	9
Diagnostic journey and life impact of cholangiocarcinoma: results from surveys of patient and caregiver experiences	9
Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy	9
Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study	9
Quality of Life Assessment in Renal Cell Carcinoma Phase II and III Clinical Trials Published between 2010 and 2020: a Systematic Review	8
Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer	8
A Real-World US Study of Recurrence Risks using Combined Clinicopathological Features in HR-Positive, HER2-Negative Early Breast Cancer	8
Expression of Interferon Regulatory Factor Family and its Prognostic value in Acute Myeloid Leukemia	8
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study	8
Treatment Patterns and Economic Burden Among Newly Diagnosed Cervical and Endometrial Cancer Patients	8
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer	8
Corrigendum	8
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer	8
Eribulin in Brain Metastases of Breast Cancer: Outcomes of the EBRAIM Prospective Observational Trial	8
Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol	8
Low-Dose Olanzapine, Sedation and Chemotherapy-Induced Nausea and Vomiting: A Prospective Randomized Controlled Study	8
ADJUBIL: Phase II Study of Adjuvant Immunotherapy with STRIDE Regimen With/Without Capecitabine in Biliary Tract Cancers	8
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design	8
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	8
OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer	8
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon	8
Corrigendum	8
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)	8
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?	8
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)	8
Systematic literature Review for the Association of Biomarkers with Efficacy of Anti-PD-1 Inhibitors in Advanced Melanoma	8
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia	8
Podcast article: Biomarker testing in colorectal cancer	8
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	8
Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies	8
Corrigendum	8
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors	8
Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors	7
Atezolizumab Plus Tivozanib for Immunologically Cold Tumor Types: The IMMCO-1 Trial	7
Prognostic Implication of Serum AFP in Patients with Hepatocellular Carcinoma Treated with Regorafenib	7
Many People with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment up to 8 Years: A Plain Language Summary	7
Increased Cytoplasmic Expression of DLL4 is Associated with Favorable Prognosis in Colorectal Cancer	7
Are Syrian refugee breast cancer patients diagnosed at advanced stage and do they have treatment delays?	7
Prognostic Significance of Hemoglobin-To-Red Cell Distribution Width Ratio in Patients with Metastatic Renal Cancer	7
Identifying and addressing the needs of caregivers of patients with cancer: evidence on interventions and the role of patient advocacy groups	7
Same-Day Versus Next-Day Pegfilgrastim or Pegfilgrastim-Cbqv in Patients with Lymphoma Receiving CHOP-Like Chemotherapy	7
Effect of multidisciplinary team-style continuity of care and nutritional nursing on lung cancer: randomized study	7
Efficacy and Safety Evaluation of PSOX, DOF and SOX Regimens as Neoadjuvant Chemotherapy for Advanced Gastric Cancer	7
Identification of PYGL as a Key Prognostic Gene of Glioma by Integrated Bioinformatics Analysis	7
Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021–2026	7
Physician Compliance with Multidisciplinary Tumor Board Recommendations for Managing Gynecological Cancers	7
Clinical Outcomes of Intensive Versus Less Intensive First-Line Chemotherapy for Metastatic Colorectal Cancer	7
A comparison of anticholinergic burden in older patients with and without cancer	7
Indirect Treatment Comparison of Oral Versus Injectable Azacitidine as Maintenance Therapy for Acute Myeloid Leukemia	7
The Genetic Polymorphisms in the SP4 Gene and the Risk of Gastric Cancer	7
Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review	7
A perioperative study of Safusidenib in patients with IDH1 -mutated glioma	7
TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer	7
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera	7
HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples	7
Real-World Cost–Effectiveness of Primary Prophylaxis with G-CSF Biosimilars in Patients at Intermediate/High Risk of Febrile Neutropenia	7
A Phase II Study of Perioperative Treatment in Gastric Cancer with No.16a2/b1 Lymph Node Metastasis: DRAGON-06 Trial	7
SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation	7
The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer	7
Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience	7
Plain Language Review: What are Biosimilar Medicines and how Can they be Used to Treat People with Cancer?	7
Risk of Toxicity with Immunotherapy–Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials	7
Correction	7
Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B	7
The Effects of Managing Cancer and Living Meaningfully (CALM) on Psychological Distress in Esophageal Cancer Patients	7
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer	7
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer	7
Circulating microRNAs as Potential Biomarkers in Triple-Negative Breast Cancer: A Translational Research Study of the NACATRINE Trial	7
Initial Treatment and Survival in Danish Patients Diagnosed with Non-Small-Cell Lung Cancer (2005–2015): SCAN-LEAF Study	6
Canakinumab with and Without Pembrolizumab in Patients with Resectable Non-Small-Cell Lung Cancer: CANOPY-N Study Design	6
The ‘Hit-and-Run’ Strategy and Viral Carcinogenesis	6
Nomograms for predicting long‐term overall survival and cancer-specific survival in chordoma: a population‐based study	6
Tremelimumab and Durvalumab in the Treatment of Unresectable, Advanced Hepatocellular Carcinoma	6
Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer	6
Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting	6